The signature predicted trametinib sensitivity in all BRAF-mutated melanomas, as expected, and in 11/15 CUPs (73%), while it predicted sensitivity only in 3/10 early metastatic tumors of known origin. The gene discussed is BRAF; the disease is metastatic neoplasm.